The results are in, Revolution Medicines stock surges on pancreatic cancer trial

Revolution Medicines (NASDAQ:RVMD) shares surged 33% Monday after the company reported positive topline results from its Phase 3 RASolute 302 clinical trial evaluating daraxonrasib in patients with metastatic pancreatic ductal adenocarcinoma who had been previously treated.

The trial met all primary and key secondary endpoints, including progression-free survival and overall survival. Daraxonrasib demonstrated a median overall survival of 13.2 months versus 6.7 months for chemotherapy, with a hazard ratio of 0.40.

The company said it intends to submit these data to global regulatory authorities, including to the U.S. Food and Drug Administration as part of a future New Drug Application under a Commissioner’s National Priority Voucher. The results will be presented at the 2026 American Society of Clinical Oncology Annual Meeting.

Daraxonrasib is a multi-selective inhibitor of RAS(ON) proteins designed to address oncogenic RAS drivers. Pancreatic cancer is the most RAS-addicted of all major cancers, with more than 90% of patients harboring tumors driven by mutations in RAS proteins.

The RASolute 302 trial enrolled patients with pancreatic tumors harboring a wide range of RAS variants, as well as those without an identified RAS mutation. The primary endpoints were progression-free survival and overall survival in patients with tumors harboring RAS G12 mutations. Secondary endpoints assessed progression-free survival and overall survival in all enrolled patients.